Full Title: The Global Market for Hormonal Contraceptives and Infertility Drugs, 2005-2012 Executive Summary Drugs in reproductive medicine are evolving into highly sophisticated products with multifunctional pharmacological properties and clinical utilities. For example, novel contraceptive formulations with low side-effect profiles are increasingly being introduced to provide women with flexible birth-control and menstrual management options whilst also offering secondary indications to treat coexisting endocrinological and gynaecological disorders. Additionally, the increasing global prevalence of infertility is driving R&D to offer novel drug solutions to improve or restore male- and female-factor infertility, optimize fertilization and embryo implantation, and reduce miscarriage.
Recent advances in administering and formulating hormone-based drugs is enabling a revolution in contraception and infertility treatments. Over the next decade, the market for hormonal contraceptives and infertility drugs is predicted to expand considerably through innovation, new and expanding markets, and high-value prospects that importantly offer novel solutions to unmet needs and demands of patients who wish to modulate or enhance fertility. The current mature market for hormonal contraceptives and infertility drugs is estimated at US$7.1 billion in 2006 but is forecast to increase 40% to US$9.9 billion by 2012.
In this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2005-2012, the reader will be introduced to an analysis of current and prospective markets, drug research and development, and company activities within the hormonal contraception and infertility therapy sectors. The report illustrates how pharmacological innovation is revolutionizing treatments to control fertility for both men and women and provides a detailed account of the new prospects that are anticipated to expand the market substantially over the next decade. Novel research and drug development areas such as male contraception and spermatogenesis induction are discussed in relation to unmet needs illustrating new trends in R&D, and the potential for high returns on investment in poorly served market segments.
The report provides a detailed analysis of the sector to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development, with promising agents further discussed from commercial and drug development perspectives.
Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into potential top-performing products; therapy forecasting to 2020 also enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling. Pages: 109 Table of Contents Download TOC in PDF
|
